A Conatus Pharmaceuticals drug developed as a treatment for chronic liver disease has failed to beat a placebo in a mid-stage study, the first of four underway for the drug.
Conatus (NASDAQ: CNAT) tested its drug, emricasan, in liver transplant patients whose hepatitis C virus has cleared, but who still have fibrosis or cirrhosis in the transplanted organ. The drug is meant to reduce the activity of enzymes that play a role in inflammation and cell death. The goal of the Phase 2b study was to assess whether the Conatus drug was better than a placebo at stopping or reversing… Read more »
UNDERWRITERS AND PARTNERS